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OBJECTIVE—The endopeptidase dipeptidyl peptidase-IV
(DPP-IV) has been shown to NH2-terminally truncate incretin
hormones, glucose-dependent insulinotropic polypeptide, and
glucagon-like peptide-1, thus ablating their ability to potentiate
glucose-stimulated insulin secretion. Increasing the circulating
levels of incretins through administration of DPP-IV inhibitors
has therefore been introduced as a therapeutic approach for the
treatment of type 2 diabetes. DPP-IV inhibitor treatment has also
been shown to preserve islet mass in rodent models of type 1
diabetes. The current study was initiated to deﬁne the effects of
the DPP-IV inhibitor sitagliptin (MK0431) on transplanted islet
survival in nonobese diabetic (NOD) mice, an autoimmune type
1 diabetes model.
RESEARCH DESIGN AND METHODS—Effects of MK0431 on
islet graft survival in diabetic NOD mice were determined with
metabolic studies and micropositron emission tomography im-
aging, and its underlying molecular mechanisms were assessed.
RESULTS—Treatment of NOD mice with MK0431 before and
after islet transplantation resulted in prolongation of islet graft
survival, whereas treatment after transplantation alone resulted
in small beneﬁcial effects compared with nontreated controls.
Subsequent studies demonstrated that MK0431 pretreatment
resulted in decreased insulitis in diabetic NOD mice and reduced
in vitro migration of isolated splenic CD4
 T-cells. Furthermore,
in vitro treatment of splenic CD4
 T-cells with DPP-IV resulted in
increased migration and activation of protein kinase A (PKA) and
Rac1.
CONCLUSIONS—Treatment with MK0431 therefore reduced
the effect of autoimmunity on graft survival partially by decreas-
ing the homing of CD4
 T-cells into pancreatic -cells through a
pathway involving cAMP/PKA/Rac1 activation. Diabetes 58:
641–651, 2009
T
he incretin hormones, glucose-dependent insuli-
notropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1), exert a number of actions that
improve glucose homeostasis, including potenti-
ation of glucose-stimulated insulin secretion (GSIS), pro-
motion of -cell proliferation and survival, and inhibition
of glucagon secretion (1–7). Because GIP and GLP-1 are
rapidly degraded by the endopeptidase dipeptidyl pepti-
dase IV (DPP-IV; CD26), it has not been possible to directly
take advantage of their beneﬁcial actions for the treatment
of type 2 diabetes (8,9). Therefore, a number of strategies
have been explored to circumvent this problem, including
the development of small molecule (10,11) and DPP-IV–
resistant peptide (12,13) incretin receptor agonists, and
DPP-IV inhibitors (14,15). Members of two classes of
compounds have recently been approved by the Food and
Drug Administration as type 2 diabetes therapeutics: the
DPP-IV–resistant GLP-1 receptor agonist (incretin mi-
metic) exenatide (Byetta) and the DPP-IV inhibitor sita-
gliptin (Januvia).
Although DPP-IV inhibitors have been extensively stud-
ied in treatment of type 2 diabetes, little is known about
their potential for treatment of type 1 diabetes. Infusion of
GLP-1 was shown to reduce glycemic excursions in type 1
diabetic patients, and this result was attributed to reduced
glucagon levels and delayed gastric emptying (16,17). In
preclinical studies, the DPP-IV inhibitor isoleucine thiazo-
lidide was shown to improve glucose tolerance in both
streptozotocin (STZ)-induced (18,19) and BioBreeding
(BB) (19) diabetic rats, associated with increased -cell
survival and possibly islet neogenesis (18). Additionally,
we recently showed that the DPP-IV inhibitor MK0431
prolonged islet graft survival in STZ-induced diabetic mice
(20). In the current study, we show that MK0431 pretreat-
ment resulted in the prolongation of islet graft survival in
an autoimmune type 1 diabetes model, the nonobese
diabetic (NOD) mouse, through a mechanism that includes
modulation of CD4
 T-cell migration.
RESEARCH DESIGN AND METHODS
NOD/LtJ mice (NOD, H2
g7) were purchased from the Jackson Laboratories
(Bar Harbor, ME). Mice (8–10 weeks old) were placed on either a normal
chow diet (Purina Rodent Chow 5015) or diet containing Sitagliptin (MK0431)
(21) (Purina Rodent Chow 5015 plus 4 g MK0431/kg; Research Diets, New
Brunswick, NJ) ad libitum. From the mice that had been fed a normal chow
diet, two groups of diabetic mice were studied. Immediately after the islet
transplantation, group 1 mice received the normal chow diet for the remainder
of the study (NCD Tx), whereas group 2 mice were fed the MK0431-containing
diet (Post MK0431 Tx). Group 3 mice were animals that had received the
MK0431 diet for 1 month before surgery and for the remainder of the study
(Pre MK0431 Tx). In a second study, mice were fed either normal chow diet
or MK0431 for a period of 4 weeks. All animal experiments were conducted in
accordance with the guidelines put forth by the University of British Columbia
Committee on Animal Care and the Canadian Council on Animal Care.
DPP-IV activity assays. To measure the plasma DPP-IV activity, a ﬂuoro-
metric assay was used as previously described (20).
Islet isolation and islet gene transfer. Islets were isolated from nondia-
betic male NOD/LtJ mice (8–12 weeks old) by collagenase digestion (22).
Recombinant adenovirus-expressing HSV1-Sr39TK was produced and ex-
panded by infection of human embryonic kidney-293 cells (23). Islets were
exposed to rAD-TK as previously described (20,24,25).
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DIABETES, VOL. 58, MARCH 2009 641Islet transplantation. A cohort of 70 female NOD/LtJ mice was divided into
two randomly selected groups of 35, and from the age of 8–10 weeks, one
group of mice received a normal chow diet while the second received a diet
containing MK0431 (4 g/kg). When mice developed diabetes, deﬁned as a
blood glucose level of 15 mmol/l for 3 consecutive days, they received an
islet transplant. Islets (200 obtained from nondiabetic male NOD/LtJ mice and
infected with 250 multiplicities of infection [MOI] of rAD-TK) were trans-
planted under the kidney capsule as described previously (20,24,25).
Plasma glucose determinations, intraperitoneal glucose tolerance
tests, and plasma hormone measurements. Nonfasting blood glucose
levels were measured in mouse-tail blood using a SureStep Glucose analyzer
(LifeScan) at the time points indicated in Figs. 1 and 2. For the intraperitoneal
glucose tolerance tests (IPGTTs), mice were fasted for 4 h, and blood glucose
levels were measured at 0, 15, 30, 60, 90, and 120 min after the glucose
challenge (2 g/kg). Blood samples with glucose levels 27.8 mmol/l were
diluted with blood from nondiabetic mice and levels calculated. Plasma
insulin, glucagon, and active GLP-1 levels were determined using a Multiplex
assay kit (Linco Research).
Synthesis of 9-(4-[
18F]-ﬂuoro-3-hydroxymethylbutyl)-guanine. 9-(4-
[
18F]-ﬂuoro-3-hydroxymethylbutyl)-guanine ([
18F]FHBG) was synthesized by a
modiﬁcation of the method of Ponde et al. (26) as previously described (24).
Micropositron emission tomography. A PET reporter gene (PRG)/PET
reporter probe (PRP) system was used, as previously described (20,24,25).
HSV1-sr39tk was expressed in islets as described above. The probe, [
18F]F-
HBG, was systemically administered and its retention in islets, after phos-
phorylation by rAD-TK, was quantiﬁed by micropositron emission tomography
(microPET) imaging. Transplanted mice were scanned using a Focus120 (CTI
Concorde) system that yielded 63 slices, 1.2 mm apart with an in-plane
resolution of 2 mm full-width at half-maximum (27). Image reconstruction and
data analysis were performed as previously described (20,24,25).
Insulitis scoring and measurement of relative -cell area. Parafﬁn-
embedded pancreatic sections were stained with hematoxylin-eosin (H-E),
and islets were examined in a blinded manner under the microscope to
evaluate the degree of mononuclear cell inﬁltration. The degree of insulitis
was scored in the following ﬁve categories: 0, intact islet; 25% of the islet
inﬁltrated; 25–50% of the islet inﬁltrated; 50–75% of the islet inﬁltrated; and
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FIG. 1. The effects of MK0431 in diabetic NOD mice after islet transplantation. A: Schematic diagram of group design. Islets isolated from
nondiabetic NOD mice were infected with 250 MOI of rAD-TK, 200 of which were transplanted under the right kidney capsule of diabetic female
NOD mice. Islet-transplanted diabetic NOD mice were fed as follows: group 1, normal chow diet throughout (NCD Tx); group 2, MK0431 diet after
transplant (Post MK0431 Tx); group 3, MK0431 diet 1 month before and after transplant (Pre MK0431 Tx). B and C: The effects of MK0431 on
plasma DPP-IV activity (B) and plasma active GLP-1 levels (C) in diabetic NOD mice after islet transplantation. D–I: The effects of MK0431 on
food consumption (D), body weight (E), water intake (F), nonfasting (G) and fasting (H) glycemic control, and survival rates (I) in diabetic NOD
mice after islet transplantation. Number of animals: n  57 per group: NCD Tx group (E), Post MK0431 Tx group (*), and Pre MK0431 Tx group
(F). All data represent means  SE, and signiﬁcance was tested using ANOVA with a Newman-Keuls post hoc test, where **P < 0.05 vs. NCD Tx.
 and E: NCD T. o and *: Post MK0431 Tx. f and F: Pre MK0431 Tx.
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642 DIABETES, VOL. 58, MARCH 200975% of the islet inﬁltrated. The degree of insulitis in 20–25 islets per mouse
was evaluated. -Cell area was measured on the sections of each pancreas
stained for insulin. Morphometric evaluation of the total -cell area was
performed by computer-assisted image analysis (Northern Eclipse ver. 6)
using light and immunoﬂuorescence microscopy. The area of insulin-positive
cells and the total area of the tissue section were evaluated for each section,
and the percentage -cell area was calculated by the ratio of the area occupied
by insulin-positive cells to the total pancreatic area.
CD4
 T-cells isolation. For isolation of T-cells, spleen cell suspensions were
prepared from female NOD mice. CD4
 T-cells were enriched using the
SpinSep Mouse CD4
 T Cell separation kit (Stem Cell Technologies), and the
purity of CD4
 T-cells was conﬁrmed by ﬂow cytometry.
Migration assay. CD4
 T-cells were plated on membrane inserts (8-m pore
size) in serum-free RPMI 1640, and cell migration was assayed using Transwell
chambers (Corning), in the presence or absence of puriﬁed porcine kidney
DPP-IV (32.1 units/mg; 100 mU/ml ﬁnal concentration; provided by Dr.
Hans-Ulrich Demuth, Probiodrug, Halle, Germany) (28)  DPP-IV inhibitor
(100 mol/l). After 1 h, cells on the upper surface were removed mechanically,
and cells that had migrated into the lower compartment were counted. The
extent of migration was then expressed relative to the control sample.
Rac1 guanosine triphosphate (GTP) binding assay. Total cellular extracts
were isolated from CD4
 T-cells and Rac1 GTP binding assays performed
using the ﬂuorophore-based RhoGEF exchange assay kit (Cytoskeleton,
Denver, CO), and data were normalized to protein concentration.
cAMP measurements. CD4
 T-cells were incubated for 30 min with GIP, 100
nmol/l GLP-1 or 100 mU/ml puriﬁed porcine DPP-IV in the presence of 0.5
mmol/l IBMX. cAMP concentration in the cell extracts was determined using
the Parameter cyclic AMP assay kit (R&D Systems).
Protein kinase A activity assay. Activity was measured using a protein
kinase A (PKA) kinase activity assay kit (Stressgen, Mississauga, ON) accord-
ing to the manufacturer’s protocol. The enzyme activity was normalized to
protein concentration, and data are shown as the relative activity to control.
Western blot analysis. Total cellular extracts were separated on a 15%
SDS-polyacrylamide gel and transferred onto nitrocellulose membranes (Bio-
Rad). Probing of the membranes was performed with antibodies to phospho-
p38 mitogen-activated protein kinase (MAPK) (threonine-180/tyrosine-182),
p38 MAPK, phospho-p42/44 MAPK (threonine-202/tyrosine-204), p42/44
MAPK, phospho–stress-activated protein kinase/Jun NH2-terminal kinase
(SAPK/JNK) (threonine-183/tyrosine-185), phospho–protein kinase B (PKB)
(serine-473), phospho-PKB (threonine-308), PKB, and -actin (Cell Signaling
Technology, Beverly, MA). Immunoreactive bands were visualized by en-
hanced chemiluminescence (Amersham Pharmacia Biotech) using horserad-
ish peroxidase–conjugated IgG secondary antibodies.
Statistical analysis. Data are expressed as means  SE. Data were analyzed
using the linear regression analysis program PRISM (GraphPad, San Diego,
CA), and area under the curves were calculated using the algorithm provided
in the Prism software package. Signiﬁcance was tested using ANOVA with
Newman-Keuls hoc test (P  0.05) as indicated in ﬁgure legends.
RESULTS
MK0431 treatment improves islet graft survival in
diabetic NOD mice. Islet-transplanted, diabetic NOD
mice were studied to determine the effect of MK0431
treatment on graft survival. Three groups of mice were
studied, as described in RESEARCH DESIGN AND METHODS: group
1 received normal chow diet throughout the study period
(NCD Tx), group 2 received MK0431 only after transplant
(Post MK0431 Tx), and group 3 received MK0431 before
and after transplant (Fig. 1A). Importantly, of mice that
were treated with MK0431 before receiving the transplant,
only 22.8% (8 of 35) became diabetic, compared with 40%
(14 of 35) of the mice receiving normal chow diet.
For the transplants, islets were infected with a rAD-TK,
recombinant adenovirus expressing HSV1-sr39tk, the
gene for a mutant form of herpes simplex virus 1 thymi-
dine kinase, to enable PET imaging (29,30), and inserted
under the kidney capsule of diabetic female NOD mice.
The effect of recombinant adenoviral infection on NOD
islet function was addressed with in vitro studies. Insulin
secretory capacity was preserved in 250 MOI rAD-TK–
treated islets, compared with untreated or control rAD--
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FIG. 1. Continued.
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DIABETES, VOL. 58, MARCH 2009 643gal virus–treated islets (supplementary Fig. 1A, available
in an online appendix at http://dx.doi.org/10.2337/db08-
1101). Furthermore, although small decreases in mean cell
viability were observed with both rAD-TK– and rAD--
gal—treated islets compared with untreated islets, these
reductions did not reach statistical signiﬁcance (supple-
mentary Fig. 1B), indicating that 250 MOI was an appro-
priate dose for further studies. The DPP-IV activity in
plasma from nondiabetic NOD mice was 67.2  4.3 mU/ml,
whereas levels measured at the time of islet transplanta-
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FIG. 2. Time-course monitoring of glucose responses, plasma chemis-
try, and islet graft survival after islet transplantation. On the indicated
days after transplantation, IPGTTs (A), plasma insulin (B), and gluca-
gon (C) levels were determined in the mice described in the legend to
Fig. 1A. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120
min after the glucose challenge (2 g/kg): NCD Tx group (), Post
MK0431 Tx group (*), and Pre MK0431 Tx group (● ). D: Time-course
monitoring of MicroPET signals detected from recipient diabetic
mice after islet transplantation. Mice described in the legend to Fig.
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18F]FHBG on the indicated days after trans-
plantation and scanned. Regions of interest were placed on the kidney
area of the microPET image, and two peak values of percent ID/g from
the two time activity curves for each region were used for determina-
tion of the signals. All data represent the mean  SE, and signiﬁcance
was tested using ANOVA with a Newman-Keuls post hoc test, where
**P < 0.05 vs. NCD Tx and ##P < 0.05 vs. 0 min, Pre MK0431 Tx.
(Please see http://dx.doi.org/10.2337/db08-1101 for a high-quality digi-
tal representation of this ﬁgure.) , NCD Tx; o, Post MK0431 Tx; f,
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93.8  16.5 mU/ml in the post-MK0431 Tx group, and
52.1  11.8 mU/ml in the pre-MK0431 Tx group (n  57
per group). Plasma DPP-IV activity in the NCD Tx group
progressively increased to levels that were 300–400%
greater than at the initiation of the study. Both pre- and
post-MK0431 Tx groups showed signiﬁcantly reduced
DPP-IV activity compared with the NCD group (Fig. 1B).
Plasma levels of active (NH2-terminally intact) GLP-1 were
signiﬁcantly increased in both pre- and post-MK0431 Tx
groups, demonstrating protection of circulating incretin
from DPP-IV–mediated degradation (Fig. 1C). For the ﬁrst
0.5 week after transplantation, the pre-MK0431 Tx group
tended to be slightly heavier (Fig. 1D), eat less food (Fig.
1E), and drink less water (Fig. 1F) than the post-MK0431
Tx group; however, this difference was not statistically
signiﬁcant. The NCD and post-MK0431 Tx groups then lost
body weight (Fig. 1D) despite their greater food and water
intake (Fig. 1E and F), whereas the pre-MK0431 Tx group
maintained body weight and food and water intake re-
mained stable (Fig. 1D–F). By 0.5 weeks after transplan-
tation, nonfasting blood glucose levels were normalized in
the pre-MK0431 Tx group, whereas levels in NCD and
post-MK0431 Tx groups progressively increased from 1
week on (Fig. 1G). A similar trend was evident for fasting
blood glucose (Fig. 1H). During the course of the study,
80% of the NCD Tx group and 40% of the post-MK0431 Tx
group died, probably as a result of the severe hyperglyce-
mia, whereas all of the pre-MK0431 Tx group survived
(Fig. 1I).
IPGTTs were performed after transplantation (n  57
animals/group). As expected, with the suboptimal trans-
planted islet mass, IPGTTs showed a rapid deterioration of
glucose handling in NCD and post-MK0431 Tx groups. By
contrast, the pre-MK0431 Tx group preserved the capacity
to regulate blood glucose levels normally until the end of
the study (Fig. 2A). Both basal and glucose-stimulated
plasma insulin levels in the NCD and post-MK0431 Tx
groups were below 6.2 pmol/l (the detection limit of the
assay), whereas the pre-MK0431 Tx group showed stable
insulin secretory responses to glucose stimulation (Fig.
2B). Although plasma glucagon levels increased substan-
tially in the NCD Tx group over the 3 weeks after trans-
plantation, glucagon levels in the post-MK0431 Tx group
remained low and were further decreased in the pre-
MK0431 Tx group (Fig. 2C). The effect of MK0431 on islet
graft survival was further assessed by microPET imaging.
The PET signal from transplanted islets in the NCD and
post-MK0431 Tx groups decreased dramatically within 1
week, whereas mice in the pre-MK0431 Tx group showed
sustained PET signals for up to 4 weeks after transplanta-
tion (Fig. 2D). These results indicated that MK0431 pre-
treatment resulted in prolongation of islet graft survival.
Modulation of the immune system in MK0431-treated
mice. In view of the reduced incidence of diabetes in the
pre-MK0431 Tx group and the prolonged islet graft sur-
vival, we considered it likely that the action of MK0431 in
NOD mice involved modulation of the immune system
during the 1-month pretreatment period. To determine
whether MK0431 administration could impact immune cell
inﬁltration of transplanted islets, the development of insu-
litis was examined in female NOD mice receiving normal
chow diet or MK0431 diets for 1 month starting at 8–10
weeks of age (Fig. 3A). By 12–14 weeks of age, the
incidence of diabetes was substantially decreased in the
MK0431 group compared with the NCD group; 17.6% (3 of
17) of the mice developed diabetes in the MK0431 group
and 35% (6 of 17) in the NCD group. Animals with glucose
15 mmol/l were grouped as “normal” and those with
glucose 15 mmol/l as “diabetic.” There were no signiﬁ-
cant differences in blood glucose levels between the
diabetic mice that had been fed normal chow diet 21.1 
2.5 (n  6) and those receiving MK0431 diet 20.7  2.8
(n  3) (Fig. 3B). However, histochemical analysis re-
vealed that islets in sections from the diabetic MK0431
group exhibited a more intact structure, whereas the
majority of islets in the diabetic NCD group showed severe
insulitis: 90 and 70% of the islets in NCD diabetic and
MK0431 diabetic mice, respectively, were inﬁltrated by
25% (Fig. 3C). Treatment with MK0431 resulted in signif-
icantly increased islet -cell area in both the mice with
normal plasma glucose and the diabetic mice: normal mice
-cell area, NCD: 0.37  0.03%; MK0432: 0.61  0.05%;
diabetic mice -cell area, 0.01  0.003%; and MK0431:
0.12  0.02% (Fig. 3D).
Mechanisms underlying the DPP-IV–mediated reduc-
tion in lymphocytic inﬁltration. Potential mechanisms
by which DPP-IV inhibitor treatment protected islets from
severe lymphocytic inﬁltration were next assessed. CD4

T-cells have been considered to be essential for the
development of diabetes through recognition of -cell
antigens in the context of the class II major histocompat-
ibility complex (MHC) I-A
g7. The identiﬁcation of an islet-
speciﬁc CD4
 T-cell clone for the acceleration of diabetes
in young NOD mice (31) led us to consider the potential
involvement of DPP-IV–mediated CD4
 T-cell migration.
The in vitro migration of splenic CD4
 T-cells isolated
from the diabetic NCD group was signiﬁcantly increased
when compared with the normal NCD group, and MK0431
treatment partially restored the levels toward normal (Fig.
3E). The extent of CD4
 T-cell migration correlated well
with plasma DPP-IV activity and blood glucose levels (r
2 
0.85, P  0.0001 for plasma DPP-IV activity and r
2  0.79,
P  0.0001 for fasting blood glucose levels; Fig. 3F and G).
These results suggested that the prolonged islet graft
survival observed in the pre-MK0431 Tx group was at least
partially due to immunomodulation.
The effect of MK0431 treatment on signaling modules
potentially involved in the regulation of CD4
 T-cell
migration was then studied. Rac1 is a member of the
	-GTPase family and has been shown to play an important
role in cytoskeletal reorganization, membrane trafﬁcking,
cell growth, and development (32,33). In view of this role,
we examined the Rac1 GTP binding activity in splenic
T-cells from normal chow diet and MK0431-treated NOD
mice. As shown in Fig. 4A, Rac1 GTP binding activity in
CD4
 T-cells of the diabetic NCD group was substantially
reduced in the diabetic MK0431-treated group. On the
other hand, there were no signiﬁcant changes in the level
of phosphorylation of a number of other signaling mole-
cules, including p38 MAPK (Thr180/Tyr182), SAPK/JNK
(Thr183/Tyr185), p42/44 MAPK (Thr202/Tyr204), PKB
(Ser473), or PKB (Thr308) (Fig. 4B–F). Further in vitro
studies were then performed to determine whether ele-
vated circulating incretins or DPP-IV itself were likely
responsible for the increase in T-cell migration and Rac1
activity. CD4
 T-cells were isolated from the spleen of
nondiabetic female NOD mice and treated with DPP-IV,
GIP, or GLP-1 in the presence or absence of DPP-IV
inhibitor. As shown in Fig. 5A, treatment of CD4
 T-cells
with DPP-IV resulted in 1.6-fold increase in T-cell migra-
tion that was abolished by DPP-IV inhibitor treatment.
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T-cell migration. In preliminary studies, similar effects of
DPP-IV on migration of human T-cell lymphoma Jurkat
cells were observed. Treatment resulted in 3.8-fold in-
creases in migration that were abolished by DPP-IV inhib-
itor treatment (supplementary Fig. 2, available in the
online appendix).
Treatment with DPP-IV also increased Rac1 GTP bind-
ing activity, whereas both GIP and GLP-1 had no effect
(Fig. 5B). There were also no signiﬁcant effects of DPP-IV,
GIP, or GLP-1, in the presence or absence of DPP-IV
inhibitor, on phosphorylation of other signaling proteins
examined (Fig. 5C–G), strongly suggesting that DPP-IV
regulates the migration of CD4
 T-cells directly via a
pathway involving Rac1.
Both PKA activation of Rac1 (34) and Rac1 activation of
PKA (35) have been described in different cell types.
Involvement of the cAMP/PKA pathway in DPP-IV action
on CD4
 T-cells was therefore studied. Treatment of
splenic CD4
 T-cells with 100 mU/ml DPP-IV for 30 min
resulted in 2.7-fold increase in cAMP concentration
compared with control, and DPP-IV inhibitor abolished the
effect (Fig. 6A). By contrast, treatment with GIP or GLP-1
(100 nmol/l) had no signiﬁcant effects on cAMP levels (Fig.
6A). MK0431 decreased DPP-IV–mediated PKA activation
in a concentration-dependent manner (Fig. 6B). The low
concentrations that resulted in inhibition support a spe-
ciﬁc action of MK0431 on DPP-IV. Additionally, MK0431
did not inhibit the PKA stimulatory effect of 6-Bnz-cAMP,
a PKA-selective, PDE-resistant cAMP analog (Fig. 6C).
This suggests that the activation is upstream of cAMP
production, probably at an extracellular level. As ex-
pected, when PKA was inhibited by either H-89 or Rp-
cAMPs, DPP-IV was no longer capable of stimulating PKA,
and DPP-IV inhibition exhibited no further effect (data not
shown). Together, these results strongly support a mech-
anism for DPP-IV–mediated PKA activation proximal to, or
at the level of, adenylate cyclase. Forskolin, a direct
activator of adenylyl cyclase, was found to mimic the
effect of DPP-IV on CD4
 T-cell migration, and responses
to both DPP-IV and forskolin were greatly reduced by
administration of the selective PKA inhibitor H-89 (Fig.
6D). Similarly, DPP-IV and forskolin both increased Rac1
GTP binding, whereas H-89 abolished their effects (Fig.
6E). Together, these results strongly suggest that DPP-IV
activates a pathway involving the production of cAMP and
activation of PKA and Rac1, resulting in increased CD4

T-cell migration.
DISCUSSION
Two major developments have been responsible for dra-
matically improving the long-term success of islet trans-
plantation and allowing islet-alone grafts: the development
of automated methods for human islet isolation (36) and
improved immunosuppression (37), culminating in what is
known as the “Edmonton Protocol” (37,38). However,
despite major successes, with current procedures, at least
two donor pancreata are generally needed to achieve
insulin independence because of the loss of islet viability
both during isolation and after transplantation. Addition-
ally, only 67% (39) and 10% (40) of transplant recipients
have been shown to be insulin independent at the end of 1
and 5 years, respectively. The causes of loss after trans-
plant are multiple, and apoptosis is thought to play a
critical role. Because the incretin hormones GIP and
GLP-1 have been reported to stimulate -cell proliferation
and survival (1–3,5–7), increasing the concentrations of
bioactive incretin hormones through DPP-IV inhibitor
treatment could offer therapeutic advantages in type 1
diabetic patients receiving islet transplants. In the present
study, MK0431 pretreatment was shown to exert beneﬁcial
effects on glycemia in mice receiving islet transplants, as
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DIABETES, VOL. 58, MARCH 2009 647indicated by metabolic studies and microPET imaging
(Figs. 1 and 2). In contrast to the preserved GSIS of the
pre- MK0431 Tx group (Fig. 2A), glucose tolerance rapidly
deteriorated in both the NCD and post-MK0431 Tx groups,
and these two groups showed greatly attenuated PET
signals (Fig. 2D). In a subsequent study, it was shown that
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FIG. 5. The effect of sDPP-IV and incretins on splenic CD4
 T-cells. CD4
 T-cells were isolated from the spleen of nondiabetic female NOD mice placed
on normal chow diet. T-cells were stimulated with puriﬁed porcine DPP-IV (100 mU/ml), GIP or GLP-1 (100 nmol/l) in the presence or absence of 100
mol/l DPP-IV inhibitor for 1 h. A: Splenic CD4
 T-cell migration. The migration of splenic CD4
 T-cells were determined using Transwell chamber
(Corning) as described in RESEARCH DESIGN AND METHODS. B: Rac1 GTP binding activity. Total cellular extracts were isolated, and Rac1 GTP binding activity
was determined. C–G: Total cellular extracts were isolated, and Western blot analyses were performed with antibodies against phosphorylated p38MAPK
(Thr180/Tyr182) (C), SAPK/JNK (Thr183/Tyr185) (D), p42/44 MAP Kinase (Thr202/Tyr204) (E), PKB (Ser473) (F), PKB (Thr308) (G), and actin. Western
blots are representative of n  3, and signiﬁcance was tested using ANOVA with a Newman-Keuls post hoc test, where **P < 0.05 vs. control.
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MK0431 group compared with that in the diabetic NCD
group (Fig. 3C), there were no signiﬁcant differences in
nonfasting blood glucose levels between the groups (Fig.
3B). Additionally, no signiﬁcant differences in nonfasting
blood glucose levels were observed even in 2-month
MK0431-pretreated mice (data not shown). However, be-
cause MK0431 treatment resulted in the preservation of
pancreatic -cells in both mice with normal glucose toler-
ance and the diabetic group (Fig. 3D), we cannot exclude
a signiﬁcant contribution from the residual islets to the
overall beneﬁcial effects of MK0431 pretreatment on gly-
cemia in the mice receiving islet transplants.
There is considerable evidence supporting a critical role
for DPP-IV in immune regulation, including delivery of a
costimulatory signal for T-cell activation (41). Acute rejec-
tion in experimental models of cardiac allograft transplan-
tation was shown to be associated with increased serum
DPP-IV activity, and inhibition resulted in abrogated acute
and accelerated rejection (42,43). Additionally, inhibition
of intragraft DPP-IV signiﬁcantly reduced ischemia/reper-
fusion-associated pulmonary injury, allowing for success-
ful lung transplantation (44). In the present study, islet
graft survival was only prolonged signiﬁcantly in the pre-
MK0431 group. Despite similar active GLP-1 levels in the
pre- and post-MK0431 Tx groups (Fig. 1C), the post-
MK0431 Tx group showed only minor improvements in
glucose homeostasis, with mean fasting glucose levels
slightly lower than the NCD Tx group over the ﬁrst 2
weeks (Fig. 1H) and a small enhancement in glucose
tolerance at 4th week (Fig. 2A). Second, NCD and post-
MK0431 Tx groups showed signiﬁcantly attenuated PET
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FIG. 6. The effect of sDPP-IV on cAMP accumulation and the
involvement of cAMP/PKA/Rac1 pathway in DPP-IV–mediated
CD4
 T-cells migration. A: DPP-IV–mediated cAMP accumula-
tion. Splenic CD4
 T-cells were stimulated for 30 min with GIP,
100 nmol/l GLP-1, or 100 mU/ml puriﬁed porcine DPP-IV in the
presence of 0.5 mmol/l IBMX, and cAMP concentrations were
determined in the cell extracts. B: Effect of MK0431 on DPP-IV–
mediated PKA activation. Splenic CD4
 T-cells were treated
with 100 mU/ml puriﬁed porcine DPP-IV in the presence of
indicated concentration of MK0431, and PKA activity was de-
termined. C: Effect of MK0431 on 6-Bnz-cAMP–mediated PKA
activation. Splenic CD4
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MK0431, and PKA was activity determined. D: Effect of PKA
inhibition on DPP-IV–mediated T-cell migration. CD4
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migration was determined. E: Effect of PKA inhibition on DPP-
IV–mediated Rac1 activation. CD4
 T-cells were treated as
described above, and Rac1 GTP binding activity was determined.
All data represent means  SE, and signiﬁcance was tested
using ANOVA with a Newman-Keuls post hoc test, where **P <
0.05 vs. control and ##P < 0.05 vs. DPP-IV.
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pre-MK0431 Tx group (Fig. 2D). These results strongly
suggest that MK0431 modulated the immune function of
DPP-IV during the 1-month pretreatment period, thus
contributing to islet graft survival in the NOD mice. The
pathogenesis of type 1 diabetes involves activation of
autoimmune T-cells followed by their homing in on the
pancreatic islets, resulting in the destruction of -cells. It
was previously reported that soluble DPP-IV (sCD26) had
an enhancing effect on transendothelial T-cell migration
mediated through its intrinsic DPP-IV enzyme activity
(45). In the present study, migration of splenic CD4

T-cells prepared from the diabetic NCD group was
signiﬁcantly increased compared with that of the non-
diabetic NCD group, and MK0431 treatment partially
restored the levels toward normal (Fig. 3E).
Active, GTP-bound Rac1 plays an important role in the
control of cell migration by regulating actin-rich lamelli-
podial protrusions that are critical for the generation of
driving force of cell movement (46). Recently, it was
shown that basal activation of Rac1 via MHC class II
molecule stimulation is essential for CD4
 T-cell motility,
and self-ligand deprivation is associated with reduced
levels of active Rac1 (47). In the present study, enhanced
Rac1 GTP binding activity in CD4
 T-cells of the diabetic
NCD group was found to be decreased in the diabetic
MK0431-treated group (Fig. 4A). Furthermore, DPP-IV
directly inﬂuenced the migration of CD4
 T-cells and Rac1
GTP binding activity (Fig. 5). It is therefore conceivable
that increased plasma DPP-IV activity in diabetic NCD
mice led to increased CD4
 T-cell migration by regulating
Rac1 GTP binding activity, whereas MK0431 attenuated
autoimmune diabetes partially through decreasing CD4

T-cell migration. Strong evidence for the involvement of
increased cAMP production and PKA activation in DPP-
IV–mediated CD4
 T-cell migration was obtained (Fig.
6A–D), although it is unclear as to the protein activation
sequence. In the current studies, DPP-IV and forskolin
activation of Rac1 (Fig. 6E) were all ablated by treatment
with the PKA inhibitor H89, suggesting that Rac1 is down-
stream of PKA. Although the effect of cAMP/PKA on cell
migration has been reported to be positive or negative
depending on the cell type, the spatial-temporal distribution
and activation of cAMP/PKA during the regulation of cell
migration are likely to be critical components of its action
(48).
Although the results reported in the present study
suggest that direct inhibitor effects on DPP-IV, and not
increased levels of active GIP and GLP-1, are mainly
responsible for the improvements in graft retention, we
have not completely ruled out a contribution from the
incretins or other factors. Additionally, the reduced inci-
dence of diabetes in the MK0431-treated group may well
involve the incretins. The long-acting GLP-1 receptor ago-
nist exendin-4, has been shown to synergize with anti-CD3
monoclonal antibody treatment in reversing diabetes in
NOD mice by enhancing the recovery of -cells (49).
Furthermore, continuous administration of GLP-1 to pre-
diabetic NOD mice reduced diabetic incidence by regulat-
ing -cell proliferation and apoptosis (50). More recently,
the GLP-1 receptor was shown to be expressed in lym-
phoid tissue, and exendin-4 treatment increased the num-
ber of CD4
 and CD8
 T-cells in the lymph nodes and
reduced the number of CD4
CD25
Foxp3
 regulatory
T-cells in the thymus, suggesting direct effects of GLP-1 on
the immune system (51). However, exendin-4 treatment
was not associated with signiﬁcant changes in the number
of CD4
 and CD8
 T-cells or B-cells in the spleen (51). In
the present study, neither GIP nor GLP-1 treatment pro-
duced signiﬁcant effects on splenic CD4
 T-cell migration
in vitro (Fig. 5), whereas DPP-IV was stimulatory. The
reason for the diverse effects of GLP-1/exendin-4 on the
different subset of T-cells in vivo is not understood, but
the potential for DPP-IV to modify additional subsets of
lymphocytes, including those in lymph nodes and the
thymus, requires further investigation. The beneﬁcial ac-
tions of DPP-IV inhibitors and DPP-IV–resistant GLP-1
receptor agonists in type 2 diabetes have mainly been
attributed to increased incretin receptor–mediated re-
sponses. Although it has been recognized that DPP-IV also
plays a signiﬁcant role in modulating immune function, no
beneﬁcial sequelae of inhibiting such actions in diabetes have
been described. The ability of the DPP-IV inhibitor MK0431 to
prolong islet graft survival by reducing immunocyte migra-
tion and islet inﬁltration suggests that the underlying cAMP/
PKA/Rac1 could be an additional drug target.
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